$MCOA Q3 shows $1.5M in debt

New Post Public Reply Private Reply Replies (0) Message Board
TradeForProfits
564
$MCOA Q3 shows $1.5M in debt cancellations

https://www.otcmarkets.com/stock/MCOA/news/Ma...?id=210851

Marijuana Company of America Announces Q3 Financial Results
Press Release | 11/20/2018
Revenue up 2984% from Q3 2017 to Q3 2018
Company achieved a 1057% decrease in net loss from operations from Q3 2017 to Q3 2018
SG&A expenses decreased by 1007% from Q3 2017 to Q3 2018.
Total assets increased by 42% from Q3 2017 to Q3 2018.
Total liabilities decreased by 259% from Q3 2017 to Q3 2018.
ESCONDIDO, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp and cannabis corporation, is pleased to announce the financial results for the three and nine months ended September 30, 2018. Here are some of the notable highlights for the third quarter of FY2018:

Total revenues were $90,276 for the three quarters ended September 30, 2018, as compared to $2,927 for the three quarters ended September 30, 2017, representing a 2984% increase quarter to quarter.
The net loss from operations decreased by 1057% from $19,047,499 for the three quarters ended September 30, 2017, to $1,801,387 for the three quarters ended September 30, 2018.
Gross profit for the third quarter of 2018 increased to $61,839 on gross sales of $90,276 (6.5% gross margin), compared to a gross margin for the third quarter of 2017 of $986.
Including non-cash items and one-time transactional expenses, SG&A expenses for the third quarter of 2018 decreased substantially by $17,160,679 or 1007% to $1.89 million, compared to $17.2 million for the fourth quarter of 2017.
For the third quarter ending September 30, 2018, the Company realized the following other one-time income items: Gain cancellation of debt of $1,500,000 and a gain of $1,175,000 from the change in value of its trading securities investment in Global Payout.
Total assets increased by 42% from $1,129,958 for the three quarters ended September 30, 2017 to $2,694,929 for the three quarters ended September 30, 2018. This increase is due primarily to the increase in value of the Company’s investment in Global Payout’s stock, which is accounted for using the trading security method of accounting as well as an increase in inventory.
Total liabilities decreased by 259% from $11,447,710 for the three quarters ended September 30, 2018 to $4,414,752 for the three quarters ended September 30, 2018. This decrease was largely due to the decrease in liabilities related to warrants and joint venture obligations.
Cash used by operating activities for the three quarters ending September 30, 2018 was $1,010,520, compared to cash used for operating activities of $527,412 for the quarter ended September 30, 2017. Cash used by investing activities for the three quarters ending September 30, 2018 was $631,886, compared to $702,419 for the three quarters ended September 30, 2017. Cash provided by financing activities for the three quarters ending September 30, 2018 was $1,460,067, compared to $1,082,345 for the three quarters ended September 30, 2017.
“The third quarter marked an important milestone for MCOA, as our hempSMART sales have ramped up due to our multi-pronged marketing campaign and several newly launched products. We ended the quarter strong with a revenue trend that is now largely stabilized with the strong foundation that we built. We expect sales to continue to increase through Q4 with the holiday season and into next year with our European expansion,” said Don Steinberg, MCOA’s CEO. Jesus Quintero, MCOA’s Chief Financial Officer, said, “The strength of the third quarter results including a substantial increase in consolidated revenue and achieving a stronger balance sheet illustrates execution of our strategic plan. MCOA is positioned to deliver on increasing levels of cash flow as we seek to stack profitable recurring revenue from our monthly autobill customers while seeking to streamline production and fulfillment costs for our products.”

Further details about the Company’s financial results are available in its annual report on Form 10K, which will be available in the investor relations section of the Company’s website at www.marijuanacompanyofamerica.com.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s juridiction.

Forward Looking Statements
This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 15

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Eco Wave Power Expands Wave Energy Project in Europe

Updated Category News Views 229

Eco Wave Power Initiates Key Infrastructure Enhancements Eco Wave Power Global AB (publ) (NASDAQ: WAVE) is excited to unveil plans for crucial upgrades at its groundbreaking wave energy project. This groundbreaking initiative is set to harness ocean wave energy to produce clean electricity efficiently. Eco Wave Power, recognized as a leading company in onshore wave energy...

Continue Reading
Key Managerial Transactions Reported by Danske Bank A/S

Updated Category News Views 162

Recent Mandatory Transaction Notifications by Danske Bank A/S Danske Bank A/S is committed to transparency in financial transactions involving its managerial personnel. This communication signifies the bank's adherence to the EU Market Abuse Regulation and the requirements set by the Danish Financial Supervisory Authority (FSA) and Nasdaq Copenhagen. Understanding...

Continue Reading
Strategic Insights into Symbotic's Options Market Activity

Updated Category News Views 187

Overview of Options Activity for Symbotic Recently, significant investors have demonstrated a notably bearish outlook on Symbotic. This trend has been evidenced by the options activity surrounding the company's stock, symbolized by SYM. The strong presence of whales entering the market indicates a shift in investor sentiment, with nuances that are crucial for...

Continue Reading
South Coast AQMD Takes Action on Oil Facilities During Violations

Updated Category News Views 267

South Coast AQMD Addresses Oil Site Violations In a determined effort to safeguard public health and air quality, the South Coast Air Quality Management District (South Coast AQMD) has recently taken enforcement action against three oil and gas facilities in Los Angeles. These actions were prompted by public complaints and confirmed violations of air quality regulations,...

Continue Reading
BAM UK & Ireland and LoadSpring Solutions Innovate Project Management

Updated Category News Views 199

BAM UK & Ireland and LoadSpring Solutions Innovate Project Management BAM UK & Ireland, a prominent name in the construction and engineering sector, has taken a bold step forward by partnering with LoadSpring Solutions. This collaboration aims to revolutionize project management through an innovative solution known as LoadSpring INSIGHTS™. This groundbreaking platform...

Continue Reading